An investigational agent dispensing log must be kept current and should contain the following information: • The subject number and initials of each subject to whom the investigational agent is administered • The date(s) and quantity of the investigational agent administered to the subject • Documentation of proper disposal of used investigational drug vials • Documentation of proper disposal (or return, at sponsor’s request) of unused investigational drug vials All records and unused supplies of the investigational agent must be available for inspection at every monitoring visit. 4.5 PRIOR, CONCOMITANT, AND EXCLUDED THERAPY During the course of the clinical study, subjects are anticipated to continue the use of prescribed medications identified during the screening procedures, consistent with study inclusion and exclusion criteria. Concomitant medications used in this study include: • 7-day antibiotic regimen scheduled 7 days after the last dose of CRS -207 prior to chemotherapy (2nd prime vaccination) and after final dose of CRS -207 when treatment is discontinued • Acetaminophen prior to each CRS-207 infusion • Folic acid and cyanocobalamin administered with pemetrexed • Anti-emetics (per investigator’s standard practice), including dexamethasone, administered with cisplatin • Medications to treat any treatment- emergent AEs Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 27 Medications to treat treatment- emergent AEs should not interfere with the study and can be used at the investigator’s discretion. Antipyretics may be used to treat fever or to prevent recurrence of fever. The details of any concomitant medications must be recorded in the case report form (CRF).